tradingkey.logo

Redhill Biopharma Ltd

RDHL

1.690USD

-0.010-0.59%
收盤 09/19, 16:00美東報價延遲15分鐘
5.63M總市值
0.49本益比TTM

Redhill Biopharma Ltd

1.690

-0.010-0.59%
關於 Redhill Biopharma Ltd 公司
RedHill Biopharma Ltd 是一家總部位於以色列的專業生物製藥公司,主要專注於胃腸道和傳染病。RedHill 推廣的胃腸道藥物包括用於治療幽門螺桿菌 (H. pylori) 感染的 Talicia 和用於治療旅行者腹瀉的 Aemcolo。RedHill 的臨牀後期開發項目包括::info: RHB-204,用於治療肺部非結核分枝桿菌 (NTM) 疾病;opaganib (ABC294640),針對多種適應症的宿主靶向 SPHK2 抑制劑,RHB-107 (upamostat),一種具有大流行防備潛力的口服宿主靶向絲氨酸蛋白酶抑制劑,正處於後期開發階段,用於治療非住院症狀性 COVID-19,並針對多種其他癌症和炎症性胃腸道疾病;RHB-104 用於克羅恩病;以及 RHB-102,用於治療化療和放療引起的噁心和嘔吐。
公司簡介
公司代碼RDHL
公司名稱Redhill Biopharma Ltd
上市日期Feb 01, 2011
CEOMr. Dror Ben-Asher
員工數量35
證券類型Depository Receipt
年結日Feb 01
公司地址21 Ha'arba'a St.
城市TEL AVIV-YAFO
上市交易所NASDAQ Capital Market Consolidated
國家Israel
郵編6473921
電話97235413131
網址https://www.redhillbio.com/
公司代碼RDHL
上市日期Feb 01, 2011
CEOMr. Dror Ben-Asher
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Shmuel Cabilly, Ph.D.
Dr. Shmuel Cabilly, Ph.D.
Independent Director
Independent Director
--
--
Ms. Patricia Anderson
Ms. Patricia Anderson
Senior Vice President - Regulatory Affairs
Senior Vice President - Regulatory Affairs
--
--
Mr. Razi Ingber
Mr. Razi Ingber
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Alexandra Okmian
Mr. Alexandra Okmian
Investor Relations
Investor Relations
--
--
Mr. Adi Frish
Mr. Adi Frish
Chief Corporate and Business Development Officer
Chief Corporate and Business Development Officer
--
--
Mr. Dror Ben-Asher
Mr. Dror Ben-Asher
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Reza Fathi, Ph.D.
Dr. Reza Fathi, Ph.D.
Senior Vice President - Research and Development
Senior Vice President - Research and Development
--
--
Mr. Ofer Tsimchi
Mr. Ofer Tsimchi
Independent Director
Independent Director
--
--
Dr. Kenneth Reed, M.D.
Dr. Kenneth Reed, M.D.
Independent Director
Independent Director
--
--
Mr. Guy Goldberg, J.D.
Mr. Guy Goldberg, J.D.
Chief Business Officer
Chief Business Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Shmuel Cabilly, Ph.D.
Dr. Shmuel Cabilly, Ph.D.
Independent Director
Independent Director
--
--
Ms. Patricia Anderson
Ms. Patricia Anderson
Senior Vice President - Regulatory Affairs
Senior Vice President - Regulatory Affairs
--
--
Mr. Razi Ingber
Mr. Razi Ingber
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Alexandra Okmian
Mr. Alexandra Okmian
Investor Relations
Investor Relations
--
--
Mr. Adi Frish
Mr. Adi Frish
Chief Corporate and Business Development Officer
Chief Corporate and Business Development Officer
--
--
Mr. Dror Ben-Asher
Mr. Dror Ben-Asher
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 9月6日 週六
更新時間: 9月6日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Heights Capital Management, Inc.
2.10%
UBS Financial Services, Inc.
0.24%
Desjardins Securities Inc.
0.10%
GAMMA Investing LLC
0.06%
SBI Securities Co., Ltd.
0.06%
其他
97.43%
持股股東
持股股東
佔比
Heights Capital Management, Inc.
2.10%
UBS Financial Services, Inc.
0.24%
Desjardins Securities Inc.
0.10%
GAMMA Investing LLC
0.06%
SBI Securities Co., Ltd.
0.06%
其他
97.43%
股東類型
持股股東
佔比
Investment Advisor
2.51%
Research Firm
0.32%
Investment Advisor/Hedge Fund
0.09%
其他
97.07%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
39
100.72K
4.39%
-24.30K
2025Q1
45
100.27K
5.67%
-27.27K
2024Q4
61
86.70K
6.77%
-35.73K
2024Q3
77
75.64K
5.91%
-52.57K
2024Q2
82
147.72K
11.56%
-10.64K
2024Q1
84
175.94K
13.78%
+109.25K
2023Q4
94
19.30K
14.67%
-65.78K
2023Q3
106
74.17K
44.30%
+53.53K
2023Q2
113
26.79K
29.96%
+840.00
2023Q1
122
24.63K
29.02%
+7.31K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Heights Capital Management, Inc.
70.00K
3.05%
+70.00K
--
Jan 25, 2024
UBS Financial Services, Inc.
2.00
0%
-4.36K
-99.95%
Mar 31, 2025
Desjardins Securities Inc.
3.39K
0.15%
--
--
Mar 31, 2025
GAMMA Investing LLC
3.57K
0.16%
-1.52K
-29.89%
Mar 31, 2025
SBI Securities Co., Ltd.
5.00
0%
+3.00
+150.00%
Mar 31, 2025
Morgan Stanley & Co. LLC
11.00
0%
-2.20K
-99.50%
Mar 31, 2025
Rhumbline Advisers Ltd. Partnership
1.39K
0.06%
+190.00
+15.86%
Mar 31, 2025
BofA Global Research (US)
303.00
0.01%
+301.00
+15050.00%
Mar 31, 2025
Yorkville Asset Management, Inc.
14.00
0%
--
--
Sep 30, 2024
查看更多
持股ETF
機構名稱
佔比
暫無數據
分紅派息
近5年累計派現 0.00 美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Aug 06, 2024
Merger
25→1
Aug 06, 2024
Merger
25→1
Aug 06, 2024
Merger
25→1
Aug 06, 2024
Merger
25→1
Mar 17, 2023
Merger
40→1
Mar 17, 2023
Merger
40→1
公告日期
類型
比率
Aug 06, 2024
Merger
25→1
Aug 06, 2024
Merger
25→1
Aug 06, 2024
Merger
25→1
Aug 06, 2024
Merger
25→1
Mar 17, 2023
Merger
40→1
Mar 17, 2023
Merger
40→1
Mar 17, 2023
Merger
40→1
Mar 17, 2023
Merger
40→1
KeyAI